(Q36744166)

16 August 2017

title

Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. (English)

1 reference

16 August 2017

1 reference

1 reference

1 reference

1 reference

Mitchell L Shiffman

1

1 reference

16 August 2017

Anastasios A Mihas

2

1 reference

16 August 2017

Farida Millwala

3

1 reference

16 August 2017

Richard K Sterling

4

1 reference

16 August 2017

Velimir A Luketic

5

1 reference

16 August 2017

R Todd Stravitz

6

1 reference

16 August 2017

Arun J Sanyal

7

1 reference

16 August 2017

language of work or name

English

0 references

publication date

23 February 2007

1 reference

The American Journal of Gastroenterology

16 August 2017

published in

1 reference

16 August 2017

volume

102

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

761-766

1 reference

Hepatitis C virus genetic variability: pathogenic and clinical implications

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

Hepatitis C in African Americans: summary of a workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

The natural history of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

Hepatitis C virus genotype 1a NS5A pretreatment sequence variation and viral kinetics in African American and white patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

Comparison of 125I-interferon-alpha binding to peripheral blood cells from African-Americans and Caucasians with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

The natural history of hepatitis C virus infection: host, viral, and environmental factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

Racial differences in HLA class II associations with hepatitis C virus outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01092.X

10.1111/J.1572-0241.2007.01092.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference